Evidence: Vital but Seldom Used Consistently by Payers
March 3rd 2020Peer-reviewed research conducted by the National Pharmaceutical Council (NPC) and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center over the past 2 years sheds some light on what’s behind discrepancies in coverage decisions from one insurer to the next.
Viability of a Dose Optimization Program Within a Specialty Pharmacy
Dose optimization strategies offer a potentially valid, clinically based intervention in which payers can realize a direct drug cost savings, and indirect medical cost avoidance.
Guselkumab Shows Efficacy as Active Psoriatic Arthritis Treatment
February 14th 2020Data from 2 studies evaluating guselkumab (Tremfya, Janssen) in active psoriatic arthritis were presented at the American College of Rheumatology and Association of Rheumatology Professionals 2019 Annual Meeting.